New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.

Area of Science:

• Neuro-oncology
• Molecular Pathology
• Pediatric Oncology

Background:

• Central nervous system primitive neuroectodermal tumors (CNS-PNETs) are aggressive embryonal tumors.
• Accurate diagnosis is crucial for effective treatment but can be challenging due to overlapping features.

Purpose of the Study:

• To molecularly reclassify institutionally diagnosed CNS-PNETs.
• To identify novel CNS tumor entities with distinct genetic alterations and clinical features.
• To facilitate improved diagnosis and therapeutic strategies for poorly differentiated CNS tumors.

Main Methods:

• Comprehensive molecular profiling of CNS-PNETs.
• Comparative analysis against established CNS tumor entities.
• Histopathological and clinical data correlation.

Main Results:

• A significant subset of CNS-PNETs were reclassified into known tumor types.
• Four novel molecular CNS tumor entities were identified: CNS neuroblastoma with FOXR2 activation (CNS NB-FOXR2), CNS Ewing sarcoma family tumor with CIC alteration (CNS EFT-CIC), CNS high-grade neuroepithelial tumor with MN1 alteration (CNS HGNET-MN1), and CNS high-grade neuroepithelial tumor with BCOR alteration (CNS HGNET-BCOR).
• Each new entity is associated with a recurrent genetic alteration and unique histopathological and clinical characteristics.

Conclusions:

• Molecular reclassification refines the diagnosis of CNS-PNETs.
• The identification of these new entities provides a foundation for developing targeted therapies.
• This work will enable more precise clinical trials for patients with poorly differentiated CNS tumors.